Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanadelumab PK/PD in Healthy Japanese and Caucasian Adults
NCT03401671Phase 1Completed
- Sponsor
- Takeda
- Start
- Jan 2018
- Primary completion
- May 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of lanadelumab in hereditary angioedema (HAE) (2 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration at 2688 hours, Time to Reach Maximum Observed Drug Concentration at 2688 hours and 6 more. Started Jan 2018; status: completed.
02
Drugs
lanadelumab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT03401671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03401671.